Recipharm
 | This article needs additional citations for verification. (May 2016) |
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceutical Contract Development and Manufacturing Organisation |
| Founded | Stockholm, Sweden, 1995 |
| Headquarters | Haninge, Sweden |
Key people | Lars Backsell, Chairman Thomas Eldered, CEO |
| Products | Pharmaceutical products for humans |
| Revenue | SEK 1,423 million (2008) |
| SEK 46 million (2008) | |
Number of employees | 1,204 (2008) |
| Website | www.recipharm.com |
Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization(CDMO), with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Recipharm employs over 1400 people and operates nine production facilities. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. Recipharm was listed on the Stockholm Stock Exchange in April 2014.
History
- 1995 - The company Recip was founded, by the owners Lars Backsell and Thomas Eldered, after a Management Buyout of a tablet production site owned by Pharmacia. Recip at this stage had 140 employees an 220 million SEK turnover.
- 1998 - Recip’s first CMO commissions for two major Nordic pharmaceutical companies. Tricum Fibres site in Höganäs, Sweden, was acquired.
- 2001 - The CMO brand Recipharm was established.
- 2002 - A penicillin plant in Strängnäs, Sweden, was acquired from AstraZeneca.
- 2004 - A semi solid facility in Karlskoga, Sweden, was acquired from AstraZeneca.
- 2005 - The organisation was restructured into separate subsidiaries.
- 2007 - A final decision was made, to focus only on outsourcing business. The distribution company with the Recip products was sold to Meda. A sterile facility was acquired in Monts, Indre-et-Loire, France, from AstraZeneca. A new development centre was obtained. A “multi-purpose” facility was acquired in Great Britain.
- 2008 - Acquisition of: Lyophilisation facility in Switzerland, A capsule production facility in Fontaine-lès-Dijon, France, The majority share of an AstraZeneca biotech laboratory in Södertälje, Sweden. About 1400 employees, turnover 1427 million SEK. The name of the company was changed from Recip to Recipharm.
- 2014 - In August, the company announced its acquisition of Corvette Pharmaceutical Services for $159 million[1] and in November the company announced it would acquire Lusomedicamenta for $140 million.[2]
- 2015 – In October the company acquired Nitin Lifesciences for $103 million.[3]
- 2016 – In February the company acquired Mitim for $75.5 million (SEK640 million)[4]